Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
November 17.2025
3 Minutes Read

Historic Moment for Patients: Cannabis-Based Medicines Education in London

Historical medical cannabis event in London with speaker and banners.

Transforming Patient Narratives into Actionable Insights

On November 7, 2025, a groundbreaking educational event was held at the Charterhouse in London, marking a historic moment for patients and the cannabis community. For the first time, patients were allowed to medicate and vape cannabis-based medicines within the historical venue, a significant breakthrough for those advocating for medical cannabis. This event, organized by We, The Patients in collaboration with PatientsCann UK, aimed to reshape the narrative around medical cannabis, placing patient voices at the heart of the conversation.

The Role of Education in Cannabinoid Research

As medical cannabis continues to gain traction globally, the need for education among healthcare professionals becomes increasingly critical. The event featured esteemed speakers like Dr. Rowan Thompson and Dr. Mikael Sodergren, who discussed current research trends and evidence supporting the use of cannabis-based medicines. With the UK Medical Cannabis Registry now home to over 50,000 patients—making it the largest of its kind worldwide—collecting real-world evidence has never been more crucial. Dr. Sodergren emphasized the potential of AI to analyze large quantities of data, helping to predict treatment responses and optimize therapy decisions.

Empowering Patients Through Storytelling

One of the most moving speeches was delivered by cannabis advocate and patient Julie Durrans, who highlighted how cannabis has positively transformed her life. "Cannabis didn’t cure me, but it gave me my life back," she shared passionately. Her words echoed the sentiments of many attendees, who have faced stigma and lack of access to effective treatment options. Durrans’s call for transparency and access to safe treatments resonates deeply with the community, pushing for policies that prioritize patient care and understanding.

A Historic Step Toward Inclusion

The event itself was significant not just for the discussions held but for the venue—a space steeped in history, dating back to medieval times. The Charterhouse, with its rich past, also symbolized a new future for patient advocacy in the UK. We, The Patients’ chair, Carola Pérez, noted, "This marks a milestone for bringing the patient voice into a historic space, allowing us to talk openly about medical cannabis. This felt like a dream come true."

This educational venture not only showcased progress in patient advocacy but also emphasized the necessity for ongoing dialogue among healthcare providers and the patients they serve. As the cannabis industry evolves, such events will be crucial in building a knowledgeable and empathetic healthcare framework that recognizes the stories behind patient experiences.

The Path Forward: Continuing the Conversation

As discussions surrounding cannabis-based medicines grow, upcoming events like the Cannabis Health Symposium on November 25 further illustrate the commitment to addressing patient needs through education and collaboration. Bringing together healthcare professionals and experts underlines the importance of shared learning, aiming to instill confidence in prescribing and utilizing cannabis in clinical settings. For those engaged in the cannabis industry, it’s clear that strengthening education and advocacy at every level will be essential to meet the demands of patients seeking safe and effective medical treatments.

In a world where narratives shape realities, the stories shared at this event have sparked a movement, driving the cannabis conversation forward. For professionals in the industry, engaging with patients’ experiences is not just beneficial; it’s imperative. The progress made thus far is commendable, but continued dialogue, education, and advocacy will ultimately determine the future of cannabis-based medicine in the UK and beyond.

Brands

0 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts

Germany's Medical Cannabis Imports Surge 19%: Will Regulations Hinder Demand?

Update Germany's Medical Cannabis Imports Surge Amid Regulatory ChangesGermany's medical cannabis landscape is experiencing a notable surge, with imports increasing by 19% recently. This spike is driven by a combination of patient demand and upcoming regulatory changes. The Federal Institute for Drugs and Medical Devices (BfArM) has expanded the country’s cannabis import cap from 122 tons to an impressive 192.5 tons, reflecting the industry’s growth.Understanding the Market DynamicsWith more than one in seven pharmacies in Germany now dispensing medical cannabis, the market is clearly maturing. According to recent data, over 43 tons were imported in just the second quarter of 2025, primarily driven by suppliers from Canada, which account for nearly half of all imports. The bustling activity from domestic players and ongoing international collaborations showcase a robust supply chain that is crucial to meeting the needs of patients nationwide.The Impact of Proposed RegulationsHowever, amidst this growth, there are looming curbs that could significantly affect patient access. The German government's proposed amendments to the Medical Cannabis Act aim to reduce accessibility by eliminating telemedicine consultations, pushing the requirement for in-person visits, and restricting mail-order deliveries. These proposed restrictions have drawn sharp criticism from many advocacy groups, including the German Hemp Association, which argues that these measures could hinder vulnerable patients’ access to vital cannabis products.Advocacy and ResistanceThe resistance from advocacy groups highlights the ongoing tension between patient needs and regulatory frameworks. While some officials claim the new regulations are necessary in light of import surges, critics argue that the pharmaceutical and medical ecosystems can adapt rather than tighten access. The outcome of these discussions will likely shape the future of the German cannabis landscape.Future Trends in Germany's Medical Cannabis MarketDespite potential regulatory hurdles, the future appears promising for Germany’s medical cannabis market. As professional and patient communities continue to push for cryptocurrency-driven facilitations and broader market access, momentum is building. Industry experts are optimistic about the potential legislation changes and the long-term growth trajectory for patient access and cannabis prescriptions.Final Thoughts on Germany’s Evolving Cannabis LandscapeThe increasing demand for medical cannabis in Germany, coupled with evolving regulations, creates a complex yet fascinating environment. Executive professionals in the cannabis sector must remain vigilant and proactive in advocating for solutions that prioritize patient welfare above bureaucratic restrictions. As we navigate this nuanced landscape, understanding both market dynamics and regulatory changes will be pivotal in shaping the future of medical cannabis in Germany.

Will Portugal Retain Its Status as the Cannabis Gateway to Europe?

Update Portugal’s Pivotal Role in European Cannabis Markets Portugal has long been seen as a crucial hub for the cannabis industry, especially since its early moves towards legalizing medical cannabis in 2018. Enthusiasts and professionals alike hailed the country as the 'gateway' to Europe’s burgeoning cannabis markets. However, recent developments suggest that this title might be in jeopardy as several other European countries ramp up their cannabis programs. The Rise of Competitors: Germany and the Czech Republic While Portugal initially enjoyed a favorable position, countries like Germany have quickly emerged as strong contenders. Germany's medical cannabis market is characterized as robust, fueled by telemedicine and significant investment, leading to an oversupply issue that has raised questions about its sustainability. Furthermore, the Czech Republic has seen substantial growth in its medical cannabis sector, positioning itself as a serious competitor in the European landscape. Exports and Medical Cannabis Supply Chains Portugal’s exports of medical cannabis products have been noteworthy, but they face stiff competition now. With countries like North Macedonia entering the market and making strides in export capabilities, Portugal must innovate its supply chains to maintain relevance. Challenges to Sustainability: Portugal’s Future Prospects The challenges of sustainability loom large. If Portugal aims to continue holding its status as a leader, it will need to address issues such as market saturation, rigor in supply chain management, and evolving consumer preferences. This need for adaptation echoes through the industry as it collectively seeks to navigate a rapidly changing regulatory environment. Building Stronger Community Connections in Cannabis As the landscape becomes more competitive, fostering community connections should remain a focus. Grassroots initiatives that support local growers and businesses are essential for cultivating a thriving cannabis ecosystem. By emphasizing these relationships, Portugal can strengthen its community’s position in the global marijuana market, ensuring sustainability and growth. Why Portugal’s Influence Will Remain Significant Despite emerging challenges, Portugal possesses a unique cultural and historical background that continues to attract investors and cannabis professionals alike. The nation’s commitment to patient care and quality standards offers a template for best practices across Europe. As the market shifts, Portugal may redefine its role, not by being merely a gateway, but as an innovator in the industry. Embracing Change: Next Steps for Portugal As the cannabis industry evolves, it will be essential for Portugal to embrace change proactively. This includes revisiting policies to align with market demands, investing in research, and improving cultivation techniques. Only by doing so can it ensure a lasting impact on the European cannabis scene and maintain its influential reputation. As cannabis professionals, understanding these dynamics is crucial for making informed decisions in an increasingly competitive landscape. Portugal's story is one of resilience, innovation, and potential for growth, making it more relevant than ever in the discussion of Europe's cannabis future.

Curaleaf and ANTG Join Forces to Revolutionize Medicinal Cannabis Access in the UK

Update A Game-Changer in UK Cannabis: Curaleaf Partners with ANTG In a landmark move for the UK cannabis industry, Curaleaf Laboratories has announced its strategic partnership with the Australian Natural Therapeutics Group (ANTG). This collaboration aims to manufacture and distribute high-quality medicinal cannabis products across the UK, potentially transforming patient access to these essential therapies. The Significance of this Partnership Curaleaf, one of the UK’s foremost providers of medicinal cannabis, is combining its advanced manufacturing capabilities with ANTG's tested reputation for delivering pharmaceutical-grade cannabis. This partnership is vital as it not only enhances product availability but also assures consistent quality and safety for both patients and healthcare professionals in the UK. Meeting Growing Demand for Medicinal Cannabis As awareness and acceptance of medicinal cannabis grow, so does the demand for reliable products. The UK has seen an uptick in patients seeking alternatives for their health conditions, driving the market for safe and effective cannabis options. Together, Curaleaf and ANTG are poised to meet this demand, adhering to stringent EU GMP (Good Manufacturing Practice) standards which guarantee the reliability of the products offered. Leadership Insights: A Commitment to Quality Richard Hodgson, Managing Director of Curaleaf Laboratories, emphasized the importance of patient access to quality cannabis medicines. “This partnership is a significant milestone for Curaleaf as we continue to support patient access to pharmaceutical-grade, evidence-based cannabis medicines.” Similarly, Matt Cantelo, CEO of ANTG, noted that this partnership aligns with their mission to improve patient outcomes through trusted, pharmaceutical-grade products. What This Means for Healthcare Professionals and Patients Starting from November 2025, the first range of ANTG products will be available on prescription from clinicians listed on the UK Specialist Register, facilitating an easier route for patients to access necessary treatments. This initiative represents a crucial step forward in advancing patient care, allowing healthcare professionals to offer more comprehensive treatment options. Conclusion: A Step Toward Improved Patient Care For executive cannabis professionals navigating this dynamic landscape, the Curaleaf-ANTG partnership is a beacon of progress within the UK’s medical cannabis sector. It not only exemplifies successful international cooperation but also underlines the industry’s potential to positively influence patient outcomes. As this partnership unfolds, it will be essential for healthcare professionals to stay informed and connected with developments to better serve their patients. For those in the cannabis industry, engaging with this evolving narrative is crucial. To learn more about opportunities and the latest products entering the market, connect with Curaleaf Laboratories. This partnership marks an exciting chapter—don’t miss out on what’s to come!

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*